Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 25:4:29.
doi: 10.1038/s41531-018-0065-1. eCollection 2018.

Help cure Parkinson's disease: please don't waste the Golden Year

Robert A Hauser  1
Affiliations

Help cure Parkinson's disease: please don't waste the Golden Year

Robert A Hauser. NPJ Parkinsons Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Relationship between time of diagnosis, need for symptomatic therapy and the opportunity for a patient to participate in an early PD disease modifying therapy trial. a The patient is diagnosed with early PD soon after the onset of motor symptoms and is enrolled in a disease modifying clinical trial. The “Golden Year” is the time from when a diagnosis of early PD can be made and the time when symptomatic therapy is needed. The red dashed line represents the potential disease slowing that might be associated with a disease modifying therapy. b The patient has waited to be evaluated until they need symptomatic therapy. They are no longer eligible to particpate in a disease modifying clinical trial and the Golden Year has been wasted. c The patient is diagnosed with early PD soon after the onset of motor symptoms but is immediately placed on symptomatic therapy. The patient is no longer eligible to participate in a disease modifying clinical trial and the Golden Year has been wasted
See this image and copyright information in PMC

References

    1. Brundin P, Dave KD, Kordower JH. Therapeutic approaches to target alpha-synuclein pathology. Exp. Neurol. 2017;298:225–235. doi: 10.1016/j.expneurol.2017.10.003. - DOI - PMC - PubMed
    1. Olanow CW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med. 2009;361:1268–1278. doi: 10.1056/NEJMoa0809335. - DOI - PubMed
    1. Athauda D, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–1675. doi: 10.1016/S0140-6736(17)31585-4. - DOI - PMC - PubMed
    1. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA, 313, 584–593 (2015). - PMC - PubMed